259 related articles for article (PubMed ID: 12387024)
1. [alpha-Glucosidase inhibitor, its structure and mechanism of antidiabetic action].
Odaka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():393-8. PubMed ID: 12387024
[No Abstract] [Full Text] [Related]
2. [Efficacy of combination therapy of alpha-glucosidase inhibitor and insulin sensitizer in patients with type 2 diabetes].
Kitaoka H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():464-9. PubMed ID: 12387035
[No Abstract] [Full Text] [Related]
3. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
Yamada K
Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
[TBL] [Abstract][Full Text] [Related]
4. [Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Nakamura J
Nihon Rinsho; 2005 Feb; 63 Suppl 2():457-61. PubMed ID: 15779422
[No Abstract] [Full Text] [Related]
5. [Effects of acarbose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Sakamoto N; Tajima N
Nihon Rinsho; 2005 Feb; 63 Suppl 2():451-6. PubMed ID: 15779421
[No Abstract] [Full Text] [Related]
6. Effect of two alpha-glucosidase inhibitors, voglibose and acarbose, on postprandial hyperglycemia correlates with subjective abdominal symptoms.
Fujisawa T; Ikegami H; Inoue K; Kawabata Y; Ogihara T
Metabolism; 2005 Mar; 54(3):387-90. PubMed ID: 15736118
[TBL] [Abstract][Full Text] [Related]
7. [Combination therapy with insulin and alpha-glucosidase inhibitor].
Watanabe K; Kawamori R
Nihon Rinsho; 2002 Sep; 60 Suppl 9():447-51. PubMed ID: 12387032
[No Abstract] [Full Text] [Related]
8. Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients.
Matsumura M; Monden T; Miyashita Y; Kawagoe Y; Shimizu H; Nakatani Y; Domeki N; Yanagi K; Ikeda S; Kasai K
Adv Ther; 2009 Jun; 26(6):660-6. PubMed ID: 19568704
[TBL] [Abstract][Full Text] [Related]
9. [Reducing postprandial glucose levels. Glucosidase antagonists].
Neye H
Pharm Unserer Zeit; 2002; 31(3):272-8. PubMed ID: 12071124
[No Abstract] [Full Text] [Related]
10. Comparison of efficacies of a dipeptidyl peptidase IV inhibitor and alpha-glucosidase inhibitors in oral carbohydrate and meal tolerance tests and the effects of their combination in mice.
Yamazaki K; Inoue T; Yasuda N; Sato Y; Nagakura T; Takenaka O; Clark R; Saeki T; Tanaka I
J Pharmacol Sci; 2007 May; 104(1):29-38. PubMed ID: 17485917
[TBL] [Abstract][Full Text] [Related]
11. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
[TBL] [Abstract][Full Text] [Related]
12. Are there different effects of acarbose and voglibose on serum levels of digoxin in a diabetic patient with congestive heart failure?
Nagai Y; Hayakawa T; Abe T; Nomura G
Diabetes Care; 2000 Nov; 23(11):1703. PubMed ID: 11092296
[No Abstract] [Full Text] [Related]
13. α-Glucosidase inhibitory effect of resveratrol and piceatannol.
Zhang AJ; Rimando AM; Mizuno CS; Mathews ST
J Nutr Biochem; 2017 Sep; 47():86-93. PubMed ID: 28570943
[TBL] [Abstract][Full Text] [Related]
14. Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation.
Standl E; Schnell O
Diab Vasc Dis Res; 2012 Jul; 9(3):163-9. PubMed ID: 22508699
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
[TBL] [Abstract][Full Text] [Related]
16. Reappraisal and perspectives of clinical drug-drug interaction potential of α-glucosidase inhibitors such as acarbose, voglibose and miglitol in the treatment of type 2 diabetes mellitus.
Dash RP; Babu RJ; Srinivas NR
Xenobiotica; 2018 Jan; 48(1):89-108. PubMed ID: 28010166
[TBL] [Abstract][Full Text] [Related]
17. Considerations when using alpha-glucosidase inhibitors in the treatment of type 2 diabetes.
Hedrington MS; Davis SN
Expert Opin Pharmacother; 2019 Dec; 20(18):2229-2235. PubMed ID: 31593486
[No Abstract] [Full Text] [Related]
18. An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.
Satoh N; Shimatsu A; Yamada K; Aizawa-Abe M; Suganami T; Kuzuya H; Ogawa Y
Metabolism; 2006 Jun; 55(6):786-93. PubMed ID: 16713439
[TBL] [Abstract][Full Text] [Related]
19. [Indication and side effect of alpha glucosidase inhibitor].
Katahira H; Ishida H
Nihon Rinsho; 2002 Sep; 60 Suppl 9():399-408. PubMed ID: 12387025
[No Abstract] [Full Text] [Related]
20. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
Scheen AJ
Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
